- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07951242
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of a Children's Fiber Blend on Digestive Health and Gut Microbiome Composition in Children
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LOAM Kids Gut Starter Fiber Formula on Digestive Health and Gut Microbiome Composition in Children
This study evaluates the impact of a fiber blend supplement on gastrointestinal symptoms and the gut microbiome in children aged 3-6 with a history or irregular stooling.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Bryce Jarman
- Telefonnummer: 323-325-1327
- E-mail: bryce@loamscience.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
- Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
- Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
- Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
- Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
- Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
- Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
- Caregiver and child reside in the United States.
- Caregiver is willing and able to provide informed consent; child assent will be obtained where age-appropriate and consistent with IRB requirements.
Exclusion Criteria:
- Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
- Child is currently breastfeeding.
- Known allergy or sensitivity to any component of the study product.
- Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
- Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
- Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
- Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
- Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
- Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
- Any planned surgical procedure during the 4-week study period.
- Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Color and taste matched placebo. |
|
Eksperimentel: Fiber Blend
|
This fiber blend contains a blend of Bifidogenic fibers and HMOs |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Stool Frequency
Tidsramme: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported number of bowel movements per week |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Stool Consistency
Tidsramme: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported stool consistency using the pediatric-adapted Bristol Stool Scale (one-seven, with one indicating hard lumpy stools and seven indicating soft liquid stools) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Digestive Comfort
Tidsramme: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Digestive comfort assessed using a visual analog scale (one-five, with one being very bad and five being very good) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Microbiome Composition
Tidsramme: Baseline, End of Study (Week 4)
|
Determined using shotgun metagenomic sequencing |
Baseline, End of Study (Week 4)
|
|
Gas and Bloating
Tidsramme: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Gas and bloating assessed using a visual analog scale (one-five, with one being never bloated and five being always bloated) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LOA005
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data is proprietary
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .